January 28, 2014
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014
Conference Call and Webcast to Follow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 28, 2014--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth
quarter and year end 2013 financial results will be released on Tuesday,
February 4, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time,
Gilead’s management will host a conference call to discuss the company’s
financial results for the fourth quarter and full year 2013 and provide
a general business update and financial guidance for 2014. The
conference call will be accessible via the internet from the company’s
website.
To access the webcast link, log on to www.gilead.com.
Please connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
1-877-280-4958 (U.S.) or 1-857-244-7315 (international) and dial the
participant passcode 69557162 to access the call. Telephone replay will
be available approximately two hours after the call through 11:59 p.m.
Eastern Time, February 7, 2014. To access the replay, please call
1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the
participant passcode 19549090. The webcast will be archived on www.gilead.com
for one year.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North and South America, Europe and
Asia Pacific.
For more information on Gilead Sciences, please visit www.gilead.com
or call the Gilead Public Affairs Department at 1-800-GILEAD-5
(1-800-445-3235).
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936
Investor
Relations
